Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Prediction of Chronic Renal Disease After Acute Kidney Injury in the Intensive Care Unit

NCT03282409 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2018-04-26
Last updated
2025-04-06

Condition(s) studied

Acute Kidney InjuryChronic Renal Disease

Study summary

The study aims to develop and validate a prediction score of chronic renal disease occurrence within 3 years after ICU discharge in patients who suffered an acute kidney failure during ICU stay and recovered normal renal function at 90 days following their discharge.

The primary study outcome is the incidence of chronic renal disease within the first 3 years after ICU discharge, defined by a lower glomerular filtration rate (GFR) under 60 mL/minute/1.73m2.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient ⩾ 18 years; * Patient suffering an acute kidney injury (defined by AKIN score ⩾1) during ICU stay; * Patient discharged alive from the ICU; * Patient's signed consent obtained; * Patient covered by a healthcare insurance. Exclusion Criteria: * Pregnant or breastfeeding woman; * SOFA score \< 1 (except for kidney assessment) at time of ICU admission; * End-stage of renal failure or dialysis treatment or renal transplantation prior to ICU admission; * Patient treated with dialysis at ICU discharge; * Immunosuppressive treatment prior to ICU admission; * Patient under legal incapacity (tutor or guardian protection); * Being unable to follow-up of the study; * Life expectancy expected shorter than 90 days; * Refusal to participate in the study; * Patient's main address is outside of Il de France region for the centers in this region; * Patient \< 18 years; * Patient not affiliated to national social security scheme; * Patient deprived of liberty by judicial measure.

Primary outcome measure(s)

  • Incidence of chronic kidney disease — At 3 years
    Incidence of chronic kidney disease defined by a decreased glomerular filtration rate (GFR) under 60 mL/minute/1.73m2.

Trial sites (1)

FacilityCityRegionStatus
Intensive care unit, Ambroise Pare Hospital Boulogne-Billancourt Hauts-de-seine
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03282409 on ClinicalTrials.gov ↗ ← All trials in France